Curated News
By: NewsRamp Editorial Staff
February 18, 2026

LIXTE Appoints CEO to Lead Proton Therapy Tech, Advances Cancer Drug Pipeline

Discuss on Substack
Original Source

TLDR

  • LIXTE appoints Sidney Braun to lead its Liora subsidiary, leveraging his expertise to scale the LiGHT proton therapy platform and pursue recurring revenue in cancer radiotherapy.
  • LIXTE's new CEO for Liora Technologies Europe will advance the LiGHT System, an electronically controlled proton therapy platform designed to enhance tumor treatment through precise radiation delivery.
  • This appointment supports LIXTE's strategy to improve cancer care by scaling advanced proton therapy technology, potentially offering better treatment outcomes for patients worldwide.
  • LIXTE taps the executive who facilitated its 2025 acquisition to lead European expansion of a cutting-edge proton therapy system for more effective cancer treatment.

Impact - Why it Matters

This development matters because it represents a dual advancement in cancer treatment—both in cutting-edge radiotherapy technology and novel pharmaceutical approaches. For patients, the LiGHT System's proton therapy platform could offer more precise tumor targeting with potentially fewer side effects than traditional radiation, while LB-100's mechanism of enhancing existing therapies might improve outcomes for hard-to-treat cancers like ovarian and colon cancers. For the healthcare industry, LIXTE's strategy of combining med-tech with drug development creates a more comprehensive approach to oncology care. The appointment of an experienced executive like Sidney Braun suggests serious commercialization efforts, which could accelerate bringing these innovations to market. In an era where cancer remains a leading cause of death globally, such multidisciplinary advances in treatment technology and pharmacology are crucial for improving survival rates and quality of life for millions affected by the disease.

Summary

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company, has announced a strategic leadership appointment to advance its cancer treatment technologies. The company has named Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary, a move that leverages Braun's more than 20 years of healthcare operational and strategic advisory experience. Braun previously facilitated LIXTE's November 2025 acquisition of Liora's assets, and his new role will focus on scaling the LiGHT System—an electronically controlled proton therapy platform designed to enhance tumor treatment precision. Management stated this appointment supports their strategy to pursue a recurring revenue model within the radiotherapy segment of cancer care, marking a significant step in commercializing advanced oncology solutions.

Beyond this executive move, LIXTE Biotechnology Holdings, Inc. is actively developing innovative cancer therapies, with its first-in-class lead clinical PP2A inhibitor, LB-100, showing promise. The company has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity, and extensive preclinical data suggests it has the potential to significantly enhance chemotherapies and immunotherapies. This compound is part of a pioneering effort in an entirely new field of cancer biology called activation lethality, which represents a new treatment paradigm covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer, positioning LIXTE at the forefront of oncology innovation.

The announcement was distributed through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on biotechnology and life sciences sectors. This platform provides enhanced press release distribution, social media outreach, and corporate communications solutions to ensure maximum impact for news like this. For investors seeking the latest updates, the company’s newsroom at https:/ibn.fm/LIXT offers ongoing information, while the full press release can be viewed at https://ibn.fm/9kbfE. This strategic leadership appointment, combined with LIXTE's robust clinical pipeline, underscores the company's commitment to transforming cancer care through both pharmaceutical and technological advancements.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, LIXTE Appoints CEO to Lead Proton Therapy Tech, Advances Cancer Drug Pipeline

blockchain registration record for this content.